References on Angiogenesis Research Using ALZET^® Osmotic Pumps

Q0757 Leksa,V., Loewe,R., Binder,B., Schiller,H.B., Eckerstorfer,P., Forster,F., Soler-Cardona,A., Ondrovicova,G., Kutejova,E., Steinhuber,E., Breuss,J., Drach,J., Petzelbauer,P., Binder,B.R., Stockinger,H. Soluble M6P/IGF2R Released by TACE Controls Angiogenesis via Blocking Plasminogen Activation. Circulation Research 2011; 108(-6-):676-U323. >>> Peptide (18-36); scrambled peptide; SC; Mice (SCID); 1002; 15 days; Animal info (pathogen-free, 6 wks old, female, CB17, scid/scid); peptides; cancer; angiogenesis.

Q0604 Gee,E., Milkiewicz,M., Haas,T.L. p38 MAPK Activity Is Stimulated by Vascular Endothelial Growth Factor Receptor 2 Activation and Is Essential for Shear Stress-Induced Angiogenesis. Journal of Cellular Physiology 2010; 222(-1-):120-126. >>> SB203580; Saline; IP; Rat; 7 days; Controls received mp w/ SB202474; animal info (male, Sprague Dawley, 150-200 g).

Q0306 Norrby,K., Nordenhem,A. Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. APMIS 2010; 118(-12-):949-957. >>> Dalteparin; epirubicin; Saline; SC; Rat; 2002; 2ML2; 14 days; Controls received mp w/ vehicle; animal info (adult, male, Sprague-Dawley, 6-7 wks old, 218-223 g.); cancer; multiple pumps per animal (2); dalteparin is a low-molecular-weight heparin; epirubicin is a chemotherapeutic.

Q0167 Sahara,M., Sata,M., Morita,T., Nakajima,T., Hirata,Y., Nagai,R. A Phosphodiesterase-5 Inhibitor Vardenafil Enhances Angiogenesis Through a Protein Kinase G-Dependent Hypoxia-Inducible Factor-1/Vascular Endothelial Growth Factor Pathway. Arterioscler Thromb Vasc Biol 2010; 30(--):1315-1324. >>> Vardenifil; PBS; SC; Mice; ; Controls received mp w/ vehicle; enzyme inhibitor (PDE5, phosphodiesterase-5); ischemia (hind limb); animal info (C57BL/6, C3H/He, 12-16 wks old, eNose -/-).

Q0307 Shenoy,V., Ferreira,A.J., Qi,Y.F., Fraga-Silva,R.A., ez-Freire,C., Dooies,A., Jun,J.Y., Sriramula,S., Mariappan,N., Pourang,D., Venugopal,C.S., Francis,J., Reudelhuber,T., Santos,R.A., Patel,J.M., Raizada,M.K., Katovich,M.J. The Angiotensin-Converting Enzyme 2/Angiogenesis-(1-7)/Mas Axis Confers Cardiopulmonary Protection against Lung Fibrosis and Pulmonary Hypertension. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 2010; 182(-8-):1065-1072. >>> A-779; Rat; 2ML4; 28 days; Animal info (5 wks old, male, Sprague Dawley).

P9489 Albertsson,P., Lennernaes,B., Norrby,K. Low-dose continuous 5-fluorouracil infusion stimulates VEGF-A-mediated angiogenesis. Acta Oncologica 2009; 48(-3-):418-425. >>> Fluorouracil, 5-; NaCl; SC; Rat; 2ML2; 14 days; Controls received mp w/ vehicle; no stress (see pg. 420); pumps primed; "No animal died during the surgical procedure or post surgical period"; angiogenesis; "The animals behaved normally and there were no signs of diarrhea or stomatitis." pg 240.

P9597 Beauvais,D.M., Ell,B.J., McWhorter,A.R., Rapraeger,A.C. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. Journal of Experimental Medicine 2009; 206(-3-):691-705. >>> Synstatin (82-130); synstatin (94-119); synstatin (92-119); cyclic RGDfv; cyclic RADfv; PBS; DMSO; H2O, double distilled; Mice (nude); 2004; 4 weeks; Controls received mp w/vehicle, or PBS; cancer; peptides; animal info (6-8 wks old, female, athymic, BALB/c); 50% DMSO used.

P9550 Hoang,S., Liauw,J., Choi,M., Choi,M., Guzman,R.G., Steinberg,G.K. Netrin-4 enhances angiogenesis and neurologic outcome after cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism 2009; 29(-2-):385-397. >>> Netrin, recomb. mouse; CSF, artificial; CSF/CNS; Mice; 1003D; ; Controls received mp w/vehicle; ischemia (focal cerebral); animal info (adult, male, C57BL/6J, 30-35g); brain tissue distribution; aCSF recipe.

Q0790 Leker,R.R., Toth,Z.E., Shahar,T., Cassiani-Ingoni,R., Szalayova,I., Key,S., Bratincsak,A., Mezey,E. TRANSFORMING GROWTH FACTOR alpha INDUCES ANGIOGENESIS AND NEUROGENESIS FOLLOWING STROKE. Neuroscience 2009; 163(-1-):233-243. >>> Transforming growth factor, alpha; CSF, artificial; CSF/CNS (infarct border); Mice; 1002; 14 days; Controls received mp w/ vehicle; animal info (C57B, male, 4-6 wks old).

Q0629 Maione,F., Molla,F., Meda,C., Latini,R., Zentilin,L., Giacca,M., Seano,G., Serini,G., Bussolino,F., Giraudo,E. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. Journal of Clinical Investigation 2009; 119(-11-):3356-3372. >>> SM-216289; SC; Mice (transgenic); 1002; 2 weeks; Controls received mp w/ saline; animal info (RipTag2 Tg, 8.5 wks old); minipump and silastic tube were sutured to the abdominal wall; cancer.

P9661 Miyake,J.A., Benadiba,M., Colquhoun,A. Gamma-linolenic acid inhibits both tumour cell cycle progression and angiogenesis in the orthotopic C6 glioma model through changes in VEGF, Flt1, ERK1/2, MMP2, cyclin D1, pRb, p53 and p27 protein expression. Lipids in Health and Disease 2009; 8(-;-):U1-U10. >>> Gamma linolenic acid; CSF, artificial; CSF/CNS (intratumoral); Rat; 2002; 14 days; Controls received mp w/vehicle; cancer (glioma); ALZET brain infusion kit used; animal info (adult, female, Wistar, 250-350).

P9897 Onimaru,M., Yonemitsu,Y., Fujii,T., Tanii,M., Nakano,T., Nakagawa,K., Kohno,R., Hasegawa,M., Nishikawa,S., Sueishi,K. VEGF-C regulates lymphangiogenesis and capillary stability by regulation of PDGF-B. American Journal of Physiology-Heart and Circulatory Physiology 2009; 297(-5-):H1685-H1696. >>> AFL-4; IP; Mice (nude); 1007D; 7 days; Controls received mp w/control antibody; animal info (male, C57BL/6J, 6 wks old, nu; BALB/C, nu, 5 wks old); AFL-4 is a murine VEGFR3-specific neutralizing antibody.

P9817 Reynolds,A.R., Hart,I.R., Watson,A.R., Welti,J.C., Silva,R.G., Robinson,S.D., Da Violante,G., Gourlaouen,M., Salih,M., Jones,M.C., Jones,D.T., Saunders,G., Kostourou,V., Perron-Sierra,F., Norman,J.C., Tucker,G.C., Hodivala-Dilke,K.M. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nature Medicine 2009; 15(-4-):392-400. >>> EMD 121974; S 36578; Saline; Mice; 2002; ; Controls received mp w/ vehicle; cancer; animal info (C57BL/6); S 36578 is a RGD- mimetic small molecule; EMD 121974 also known as Cilengitide; dose response (fig. 1, pg. 393).

P9819 Savai,R., Langheinrich,A.C., Schermuly,R.T., Pullamsetti,S.S., Dumitrascu,R., Traupe,H., Rau,W.S., Seeger,W., Grimminger,F., Banat,A. Evaluation of Angiogenesis Using Micro-Computed Tomography in a Xenograft Mouse Model of Lung Cancer. NEOPLASIA 2009; 11(-1-):48-56. >>> Bevacizumab; IV (jugular); Mice (nude); 2002; 14 days; Controls received mp w/ distilled water; animal info (female, C57BL/6, 5-7 wks old, BALB/c, nu/nu, 7-8 wks old); pump implated IP; bevacizumab is a anti-VEGF antibody; "This delivery (using ALZET pumps) mimics local delivery of antivascular agents and can be used effectively alone or in combination with cytotoxic chemotherapy for site-specific drug delivery for lung cancer treatment. As expected, continuous infusion of bevacizumab decreased lung tumor volume and tumor perfusion, with an added survival advantage compared to the untreated group." pg 55; cancer (lung); antibody.

Q0490 Takeda,Y., Uemura,S., Iwama,H., Imagawa,K.I., Nishida,T., Onoue,K., Takemoto,Y., Soeda,T., Okayama,S., Somekawa,S., Ishigami,K.I., Takaoka,M., Kawata,H., Kubo,A., Horii,M., Nakajima,T., Saito,Y. Treatment With Recombinant Placental Growth Factor (PIGF) Enhances Both Angiogenesis and Arteriogenesis and Improves Survival After Myocardial Infarction. CIRCULATION JOURNAL 2009; 73(-9-):1674-1682. >>> Placental growth factor, recomb. human; flt-1, recomb. human, soluble; IP; Mice; 3, 7 days; Controls received mp w/ vehicle; animal info (C57BL/6, 12 wks old); polyethylene IP catheter used.

Q0678 Thatch,K.A., Mendelson,K.G., Haber,M.M., Schwartz,M.Z. Growth Factor Manipulation of Intestinal Angiogenesis: A Possible New Paradigm in the Management of Inflammatory Bowel Disease. Journal of Surgical Research 2009; 156(-2-):245-249. >>> Hepatocyte growth factor, recomb. human; HCl, Tris; PBS; IV (jugular); Rat; 1002; 14 days; Controls received mp w/ saline; animal info (female, adult, Fisher).

P8780 Albertsson,P., Lennernaes,B., Norrby,K. Dose effects of continuous vinblastine chemotherapy on mammalian angiogenesis mediated by VEGF-A. Acta Oncologica 2008; 47(-2-):293-300. >>> Vinblastine sulfate; Saline, physiological; SC; Rat; 2001; 2ML1; 6-10 days; Controls received mp w/ vehicle; dose-response (fig. 2); no stress (see pg. 296); cancer; animal info (male, Sprague Dawley, 217-219g.).

P9182 Alonso,G., Gallibert,E., Lafont,C., Guillon,G. Intrahypothalamic angiogenesis induced by osmotic stimuli correlates with local hypoxia: A potential role of confined vasoconstriction induced by dendritic secretion of vasopressin. Endocrinology 2008; 149(-9-):4279-4288. >>> Vasopressin, 1-deamino-8-D-arginine; CSF/CNS; Rat; 1007D; 3, 6 days; Controls received mp w/ PBS; animal info (male, Wistar, Long Evans); dAVP; 26 gauge 10 mm cannula used.

P9027 Belabbas,H., Zalvidea,S., Casellas,D., Moles,J.P., Galbes,O., Mercier,J., Jover,B. Contrasting effect of exercise and angiotensin II hypertension on in vivo and in vitro cardiac angiogenesis in rats. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 2008; 295(-5-):R1512-R1518. >>> Angiotensin II; SC; Rat; 2002; 10 days; Controls received mp w/ vehicle; peptides; animal info (Sprague Dawley, 6 wks old).

P9287 Brahn,E., Banquerigo,M.L., Lee,J.K., Park,E.J., Fogler,W.E., Plum,S.M. An Angiogenesis Inhibitor, 2-Methoxyestradiol, Involutes Rat Collagen-Induced Arthritis and Suppresses Gene Expression of Synovial Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor. Journal of Rheumatology 2008; 35(-11-):2119-2128. >>> Estradiol, 2-methoxy-; SC; Rat; 2ML4; 18 days; Controls received mp w/ vehicle; comparison of oral gavage vs. mp; animal info (syngeneic LOU, 8-10 wks old, 100-150 g., Collagen-induced arthritis; "Delivery of 60 mg/kg by an osmotic pump, however, was similar in efficacy to 300 mg/kg oral gavage. This result suggests that a steady-state level of 2ME2 achieved equivalent arthritic inhibition at a lower total dose." (p. 2124).

R0276 Cooke,J.P., Ghebremariam,Y.T. Endothelial Nicotinic Acetylcholine Receptors and Angiogenesis. TRENDS IN CARDIOVASCULAR MEDICINE 2008; 18(-7-):247-253. >>> Mecamylamine; Mice; 2 weeks; REVIEW, see Kiuchi et a.

P8933 Fujii,T., Yonemitsu,Y., Onimaru,M., Inoue,M., Hasegawa,M., Kuwano,H., Sueishi,K. VEGF function for upregulation of endogenous PlGF expression during FGF-2-mediated therapeutic angiogenesis. Atherosclerosis 2008; 200(-1-):51-57. >>> Antibody, anti-VEGF; IP; Mice; 1007D; ; Ischemia (hind limb); animal info (male, C57BL/6, 6-7 wks old).

P9031 Jin,D.H., Yamahara,K., Harada,K., Ohnishi,S., Kangawa,K., Nagoya,N. Adrenomedullin Induces Lymphangiogenesis and Ameriolates Secondary Lymphedema. Circulation 2008; 118(-18-):S507-S507. >>> Adrenomedulin, recomb. human; Saline; SC; Mice; 14 days; Controls received mp w/ vehicle; peptides; animal info (male, BALB/c, 8-10 wks old).

P9143 Kim,J.W., Choi,Y.L., Vallentin,A., Hunrichs,B.S., Hellerstein,M.K., Peehl,D.M., Mochly-Rosen,D. Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Research 2008; 68(-16-):6831-6839. >>> TAT (47-57); IIV5-3, beta-; Saline; Mice (nude); 2001; 5 weeks; Controls received mp w/ vehicle or TAT (47-57); pumps replaced every 2 weeks; half-life (p. 6832) ~ 2 wks; enzyme inhibitor (PKC betaII, protein kinase C); animal info (6 wks old, male).

P8511 Clarkson,A.N., Liu,H., Schiborra,F., Shaw,O., Sammut,I.A., Jackson,D.M., Appleton,I. Angiogenesis as a predictive marker of neurological outcome following hypoxia-ischemia. Brain Research 2007; 1171(--):111-121. >>> Clomethiazole; L-NAME; SC; Rat; 2ML1; 5 days; Controls received mp w/ vehicle or saline or no treatment; no stress (see pg. 112); enzyme inhibitor (NO synthase); ischemia (cerebral); animal info (male, Wistar, 21 days old).

P8610 Dietrich,T., Onderka,J., Bock,F., Kruse,F.E., Vossmeyer,D., Stragies,R., Zahn,G., Cursiefen,C. Inhibition of Inflammatory Lymphangiogenesis by Integrin alpha 5 Blockade. American Journal of Pathology 2007; 171(-1-):361-372. >>> JSM6427; JSM6424; SC; Mice; 2 weeks; Controls received mp w/ vehicle; functionality of mp verified by mp and plasma levels analysis; dose-response (p. 368); pumps replaced after one week; half-life (p. 363) "rapid;" cardiovascular; immunology; animal info (BALB/C, 6 weeks old, suture-induced inflammatory corneal neovascularization); integrin a5B1 and avB3 antagonists; angiogenesis; lymphangiogenesis.

P8366 Dorrell,M.I., Aguilar,E., Scheppke,L., Barnett,F.H., Friedlander,M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2007; 104(-3-):967-972. >>> Vascular endothelial growth factor, aptamer; EMD472523; T2-TrpRS; PBS; CSF/CNS (intratumoral); Rat; 2001D; 2ML2; 2ML4; 3,6 days; 24 hours; Controls received mp w/ vehicle; cancer (gliosarcoma); animal info (male, Fischer, 344); EMD472523 is an integrin antagonist, VEGF aptamer is chemically identical to Macugen; T2 is a proteolytic fragment of tryptophan tRNA synthetase; all agents have angiostatic activity; tissue perfusion (tumor).

P8520 Kumar,R., Knick,V.B., Rudolph,S.K., Johnson,J.H., Crosby,R.M., Crouthamel,M.C., Hopper,T.M., Miller,C.G., Harrington,L.E., Onori,J.A., Mullin,R.J., Gilmer,T.M., Truesdale,A.T., Epperly,A.H., Boloor,A., Stafford,J.A., Luttrell,D.K., Cheung,M. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. MOLECULAR CANCER THERAPEUTICS 2007; 6(-7-):2012-2021. >>> GW771806; SC; Mice (nude); mice (SCID); 2001; 5,6,21 days; Controls received mp w/ vehicle; dose-response (fig. 4); comparison of oral gavage vs. mp; cancer (colon); animal info (female, Swiss nu/nu, 8-12 weeks old); VEGFR inhibitor; "Continuous infusion of VEGFR inhibitor is more effective in controlling tumor growth and angiogenesis than p.o bolus dosing." (p. 2018).

P8226 Michaud-Levesque,J., Demeule,M., Beliveau,R. In vivo inhibition of angiogenesis by a soluble form of melanotransferrin. Carcinogenesis 2007; 28(-2-):280-288. >>> Melanotransferrin, soluble, truncated recomb. human; melanotransferrin, [125I]-soluble, truncated recomb. human; Ringers's solution; HEPES solution; SC; Mice (nude); 1007D; 7 days; Controls received mp w/ vehicle; dose-response (fig. 6); comparison of SC injections vs. mp; half-life (p. 285) ~7.6 hours + or - 0.9 hours; cancer; peptides; animal info (female, athymic CD-1-nuBr, 5-10 weeks old); "The use of ALZET osmotic pump infusion technique provided a higher therapeutic efficacy as compared with repeated S.C. injections, emphasizing the advantages of constant infusion rather than pulse-dose drug inputs for antiangiogenic effects." (p. 287).

P8635 Milkiewicz,M., Doyle,J.L., Fudalewski,T., Ispanovic,E., Aghasi,M., Haas,T.L. HIF-1 alpha and HIF-2 alpha play a central role in stretch-induced but not shear-stress-induced angiogenesis in rat skeletal muscle. JOURNAL OF PHYSIOLOGY-LONDON 2007; 583(-2-):753-766. >>> DMAG, 17-; Dextrose, sterile; SC; IM (extensor digitorum longus); Rat; 2002; 7, 14 days; Controls received mp w/ vehicle; enzyme inhibitor (Hsp 90); post op. care (butorphanol); ischemia (muscle); animal info (male, Sprague-Dawley, 200-250g); agent also known as NSC 707545, a geldanamycin derivative.

P8631 Powell,JA Jr, Mousa,S.A. Neutrophil-Activating Protein-2- and Interieukin-8-Mediated Angiogenesis. Journal of Cellular Biochemistry 2007; 102(-2-):412-420. >>> Fibroblast growth factor-2, basic, human; penicillamine, S-nitroso N-acetyl; glutathione, S-nitroso N-acetyl; SC; Mice; 14 days; Peptides; animal info (male, C57BL/6, 6-8 wks old); SNAP and SNAG are nitric oxide donors.

P8542 Sakai,T., Balasubramanian,K., Maiti,S., Haider,J.B., Schroit,A.J. Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis. American Journal of Pathology 2007; 171(-5-):1659-1669. >>> Glycoprotein 1, B-2-; glycoprotein 1, nicked B-2-; SC; IP; Mice; 2002; 28 days; Controls received mp w/ HSA; cancer (prostate adenocarcinoma); peptides; multiple pumps per animal (2); animal info (male, C57BL/6, 6 weeks old); B2GP1 is also known as apolipoprotein H; mp implanted IP on day 1, SC on day 14, implanted pumps not removed.

P8275 Tanabe,K., Maeshima,Y., Ichinose,K., Kitayama,H., Takazawa,Y., Hirokoshi,K., Kinomura,M., Sugiyama,H., Makino,H. Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model. Kidney International 2007; 71(-3-):227-238. >>> Endostatin (1-27), human; PBS; SC; Mice; 2004; 24 days; Controls received mp w/ vehicle; dose-response (fig. 1); no stress (see pg. 234); animal info (male, ICR, female, 6 weeks old, 27 grams, peritoneal sclerosis); "Continuous administration of endostatin peptide via subcutaneous osmotic minipumps did not produce any harmful side effects...In addition, treatment with endostatin peptide did not give rise to any pathological alterations in the heart, liver, or kidney, and failed to affect wound repair" (p. 234); nephrology.

P8704 Tummalapalli,P., Spomar,D., Gondi,C.S., Olivero,W.C., Gujrati,M., Dinh,D.H., Rao,J.S. RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. INTERNATIONAL JOURNAL OF ONCOLOGY 2007; 31(-5-):1039-1050. >>> RNA, small interfering; Mice (nude); 3-4 weeks; Controls received no treatment; cancer (meningioma); animal info (athymic, nude); siRNA plasmid vectors targeting cathepsin B and matrix metalloproteinase MMP9.

P8163 Boodhwani,M., Mieno,S., Voisine,P., Feng,J., Sodha,N., Li,J., Sellke,F.W. High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine. Journal of Thoracic and Cardiovascular Surgery 2006; 132(-6-):1299-1306. >>> Vascular endothelial growth factor 165, recomb. human; Heparin; Perivascular (circumflex coronary artery); Mini-pig; 2ML4; 4 weeks; Cardiovascular; peptides; ischemia (cardiac); animal info (male, female, yucatan, 20-30 kg, 23 weeks old).

P8288 Capoccia,B.J., Shepherd,R.M., Link,D.C. G-CSF and AMD3100 mobilize monocytes into the blood that stimulate angiogenesis in vivo through a paracrine mechanism. Blood 2006; 108(-7-):2438-2445. >>> Granulocyte colony-stimulating factor, recomb. human; PBS; SC; Mice; mice (transgenic); 5, 7 days; Controls received mp w/ vehicle; cardiovascular; peptides; ischemia (hind limb); animal info (C57BL/6, 8-10 weeks old); ischemia; acute vascular injury.

P8109 Dirkx,A.E.M., Egbrink,M.G.A.O., Castermans,K., van der Schaft,D.W.J., Thijssen,V.L.J.L., Dings,R.P.M., Kwee,L., Mayo,K.H., Wagstaff,J., Steege,J.C.A.B., Griffioen,A.W. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB Journal 2006; 20(-6-):621-630. >>> Anginex; endostatin; BSA; angiostatin; Saline; SC; Mice; 2 weeks; 7, 11 days; Controls received mp w/ BSA or no treatment; dose-response (fig.5); cancer (melanoma, colon carcinoma); animal info (C57BL/6).

R0235 Folkman,J. Angiogenesis. Annual Review of Medicine 2006; 57(--):1-18. >>> Endostatin, recomb.; IP; Mice; ; Cardiovascular; ALZET see pg. 8.

P7748 Huang,X.L., Brown,C., Ni,W.H., Maynard,E., Rigby,A.C., Oettgen,P. Critical role for the Ets transcription factor ELF-1 in the development of tumor angiogenesis. Blood 2006; 107(-8-):3153-3160. >>> Peptide A1; peptide A1, mutant; PBS; SC; Mice (nude); 10,14 days; Controls received mp w/ vehicle; no stress (see pg. 3157); cancer (B16 melanoma); peptides; animal info (C57BL/6, female); peptide A1 is composed of ETS sequences and a 12-amino acid HIV-TAT protein-transducing membrane peptide.

P8346 Otsuka,H., Akashi,H., Murohara,T., Okazaki,T., Shintani,S., Tayama,K., Sasaki,K., Imaizumi,T., Aoyagi,S. The prostacyclin analog beraprost sodium augments the efficacy of therapeutic angiogenesis induced by autologous bone marrow cells. Annals of Vascular Surgery 2006; 20(-5-):646-652. >>> Beraprost, sodium; Saline; isotonic; SC; Rabbit; 4 weeks; Controls received mp w/ vehicle; cardiovascular; ischemia (hindlimb); animal info (male, New Zealand white, 2.4-2.6 kg).

P7608 Xia,C.F., Yin,H., Borlongan,C.V., Chao,J., Chao,L. Postischemic infusion of adrenomedullin protects against ischemic stroke by inhibiting apoptosis and promoting angiogenesis. Experimental Neurology 2006; 197(-2-):521-530. >>> Adrenomedullin, human; calcitonin gene-related peptide (8-37); Saline; SC; Rat; 7, 14 days; Controls received mp w/ vehicle; cardiovascular; peptides; ischemia (cerebral); animal info (male, Sprague-Dawley 220 g);"continuous and longterm infusion of AM starting at day 1 after I/; MCAO.

P6908 Alonso,G., Galibert,E., Duvoid-Guillou,A., Vincent,A. Hyperosmotic stimulus induces reversible angiogenesis within the hypothalamic magnocellular nuclei of the adult rat: a potential role for neuronal vascular endothelial growth factor. BMC NEUROSCIENCE 2005; 6(--):U1-U19. >>> Antibody, anti-vascular endothelial growth factor; PBS; CSF/CNS (supraoptic nucleus); Rat; 1007D; 6 days; Schematic fig 9; 10 mm, 26 gauge cannula used.

P7136 Bandyopadhyay,A., Wang,L., Loepz-Casillas,F., Mendoza,V., Yeh,I.T., Sun,L.Z. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. PROSTATE 2005; 63(-1-):81-90. >>> Transforming growth factor-B3 receptor, recomb. soluble; PBS; SC; Mice (nude); 2002; 14 days; Controls received mp w/ vehicle; comparison of IP injections vs. mp; no stress (see pg. 84,88); cancer (prostate); multiple pumps per animal (2).

P7233 Haviv,F., Bradley,M.F., Kalvin,D.M., Schneider,A.J., Davidson,D.J., Majest,S.M., McKay,L.M., Haskell,C.J., Bell,R.L., Nguyen,B., Marsh,K.C., Surber,B.W., Uchic,J.T., Ferrero,J., Wang,Y.C., Leal,J., Record,R.D., Hodde,J., Badylak,S.F., Lesniewski,R.R., Henkin,J. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: Design, synthesis, and optimization of pharmacokinetics and biological activities. Journal of Medicinal Chemistry 2005; 48(-8-):2838-2846. >>> ABT-510; Dextrose solution; water; SC; Mice; 2001; 7, 14 days; Controls received mp w/ vehicle; dose-response (fig. 6); half-life (p. 2838); cancer (lung carcinoma); peptides.

P7179 Jacobi,J., Sydow,K., von Degenfeld,G., Zhang,Y., Dayoub,H., Wang,B.Y., Patterson,A.J., Kimoto,M., Blau,H.M., Cooke,J.P. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 2005; 111(-11-):1431-1438. >>> L-NAME; dimethylarginine, asymmetric; PBS; SC; IP; Mice; mice (transgenic); 2002; 2004; 2, 3 weeks; Controls received mp w/ vehicle; enzyme inhibitor (nitric oxide synthase); cardiovascular; ischemia (hindlimb).

P7326 Kishore,R., Qin,G.J., Luedemann,C., Bord,E., Hanley,A., Silver,M., Gavin,M., Goukassain,D., Losordo,D.W. The cytoskeletal protein ezrin regulates EC proliferation and angiogenesis via TNF-alpha-induced transcriptional repression of cyclin A. Journal of Clinical Investigation 2005; 115(-7-):1785-1796. >>> Uridine, bromodeoxy-; Mice (nude); 7 days; Cardiovascular; ischemia (hindlimb); labeling of ischemic hind limb muscle.

P7248 Lakka,S.S., Gondi,C.S., Dinh,D.H., Olivero,W.C., Gujrati,M., Rao,V.H., Sioka,C., Rao,J.S. Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. Journal of Biological Chemistry 2005; 280(-23-):21882-21892. >>> RNA, small interfering; RNA, small interfering, uPAR; RNA, small interfering, MMP-9; CSF/CNS; Mice (nude); 1002; 2 weeks; Controls received mp w/ PBS or empty vector; cancer (glioblastoma); siRNA is within a plasmid vector (pUM vector); antiangiogenesis; gene therapy.

P7307 Nakagawa,K., Sasaki,Y., Kato,S., Kubodera,N., Okano,T. 22-oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 2005; 26(-6-):1044-1054. >>> Vitamin D3, 1, 25-dihydroxy-; vitamin D3, 22-oxa-la, 25-dihydroxy-; Tween 20; ethanol; SC; Mice; 2ML4; 3 weeks; 10, 18 days; Controls received mp w/ vehicle; dose-response; cancer (lung carcinoma); 10% ethanol; millipore chamber ring; sc dorsal air sac model.

P6352 Akhtar,N., Padilla,M.L., Dickerson,E.B., Steinberg,H., Breen,M., Auerbach,R., Helfand,S.C. Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. NEOPLASIA 2004; 6(-2-):106-116. >>> Interleukin-12; PBS; SC; Mice (SCID); 2004; 1 week; Controls received mp w/ vehicle; functionality of mp verified by pump explantation, examination and tumor reduction; cancer (Hemangiosarcoma); peptides; pump model not listed; tumor cells from a canine.

P6774 Bello,L., Lucini,V., Costa,F., Pluderi,M., Giussani,C., Acerbi,F., Carrabba,G., Pannacci,M., Caronzolo,D., Grosso,S., Shinkaruk,S., Colleoni,F., Canron,X., Tomei,G., Deleris,G., Bikfalvi,A. Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma. Clinical Cancer Research 2004; 10(-13-):4527-4537. >>> PEX, recomb. human; PF-4/CTF; P4-4/DLR; vascular endothelial growth inhibitor, cyclo-; Water, sterile; SC; Mice; mice (nude); 2004; 28, 112, 140 days; Dose-response; long-term study; pumps replaced every 28 days; no stress (see pg. 4532); cancer (glioma); peptides; "The treatment was always very well tolerated without the occurrence of any side effects." (p. 4532); angiogenesis inhibitor.

P6634 Croll,S.D., Ransohoff,R.M., Cai,N., Zhang,Q., Martin,F.J., Wei,T., Kasselman,L.J., Kintner,J., Murphy,A.J., Yancopoulos,G.D., Wiegand,S.J. VEGF-mediated inflammation precedes angiogenesis in adult brain. Experimental Neurology 2004; 187(-2-):388-402. >>> Vascular endothelial growth factor 164, mouse; Flt-Fc; angiopoietin I, human; angiopoietin II, human; PBS; CSF/CNS (frontoparietal cortex); Rat; 2002; 1,2,3,4,5,7 days; Controls received mp w/ vehicle or hFc; dose-response (fig. 1); brain tissue distribution; peptides; cyanoacrylate adhesive (Loctite 495).

P6720 Gondi,C.S., Lakka,S.S., Dinh,D.H., Olivero,W.C., Gujrati,M., Rao,J.S., Rao,J.S. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. ONCOGENE 2004; 23(--):8486-8496. >>> RNA, small interfering; EV/SV vector; PBS; CSF/CNS (intratumoral); Mice (nude); ; Controls received mp w/ vehicle; tissue perfusion (tumor); cancer (glioma); gene therapy; antiangiogenesis; siRNA (cathepsin B); pump model not stated (0.25 ul/hr); "...local intracranial delivery of pcu using mini-osmotic pumps effectively inhibited human malignant glioma growth.".

P6834 Hashiya,N., Jo,N., Aoki,M., Matsumoto,K., Nakamura,T., Sato,Y., Ogata,N., Ogihara,T., Kaneda,Y., Morishita,R. In vivo evidence of angiogenesis induced by transcription factor ets-1 - Ets-1 is located upstream of angiogenesis cascade. Circulation 2004; 109(-24-):3035-3041. >>> Antibody, anti-vascular endothelical growth factor; antibody, immunoglobulin G, rabbit; IP; Mice; ; Cardiovascular; ischemia.

P6576 Khatri,J.J., Johnson,C., Magid,R., Lessner,S.M., Laude,K.M., Dikalov,S.I., Harrison,D.G., Sung,H.J., Rong,Y., Galis,Z.S. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation 2004; 109(-4-):520-525. >>> Ebselen; DMSO; SC; Mice (transgenic); 14 days; Controls received mp w/ vehicle; cardiovascular; 50% DMSO; ebselen is a glutathione peroxidase-mimetic antioxidant (a.k.a Harmokisane).

P6618 Lakka,S.S., Gondi,C.S., Yanamandra,N., Olivero,W.C., Dinh,D.H., Gujrati,M., Rao,J.S. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. ONCOGENE 2004; 23(-27-):4681-4689. >>> RNA, small interfering; human cytomegalovirus promoter; Empty vector; CSF/CNS; Mice; 2004; 5 weeks; Cancer (glioblastoma); siRNA against mmp-9 and cathepsin; antiangiogenesis; gene therapy.

P7037 Lei,L., Zhou,R.F., Zheng,W., Christensen,L.P., Weiss,R.M., Tomanek,R.J. Bradycardia induces angiogenesis, increases coronary reserve, and preserves function of the postinfarcted heart. Circulation 2004; 110(-7-):796-802. >>> Alinidine; Rat; 3,7,21 days; Controls received mp w/ vehicle; ischemia (cardiac); cardiovascular; echocardiograph (ECG); KaTp channel antagonist.

P6370 Manoonkitiwongsa,P.S., Schultz,R.L., McCreery,D.B., Whitter,E.F., Lyden,P.D. Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis. Journal of Cerebral Blood Flow and Metabolism 2004; 24(-6-):693-702. >>> Vascular endothelial growth factor; Saline; IA (carotid); Rat; 2001; 7 days; Controls received mp w/ vehicle; dose response (p. 697); stroke; ischemia (cerebral); biocompatible glue was used to secure catheter in artery.

P6498 Nakamura,E.S., Koizumi,K., Kobayashi,M., Saiki,I. Inhibition of lymphangiogenesis-related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproteinase inhibitor MMI270. CANCER SCIENCE 2004; 95(-1-):25-31. >>> MMI270; DMSO; PEG 300; IP; Mice; 2004; 15 days; Controls received mp w/ vehicle; no stress (see pg.27); enzyme inhibitor (matrix metalloproteinase); cancer (lung); MMI270 was formerly termed CGS27023A; 50% DMSO "The continuous administration of MMI270 for 15 days using an osmotic pump led to a significant decrease in the weight of tumor-metastasized lymph nodes" (p. 29).

P6556 Nap,A.W., Griffioen,A.W., Dunselman,G.A.J., Bouma-Ter Steege,J.C.A., Thijssen,V.L.J.L., Evers,J.L.H., Groothuis,P.G. Antiangiogenesis therapy for endometriosis. Journal of Clinical Endocrinology and Metabolism 2004; 89(-3-):1089-1095. >>> Endostatin; anginex; SC; Mice (nude); 1002; 2 weeks; Controls received SC saline daily; no stress (see pg.1092); peptides; "The angiostatic agents did not appear to affect the overall health of the mice...The behavior of the mice during treatments was normal as well." (p. 1092).

P6792 Norrby,K. Human apo-lactoferrin enhances angiogenesis mediated by vascular endothelial growth factor A in vivo. JOURNAL OF VASCULAR RESEARCH 2004; 41(-4-):293-304. >>> Lactoferrin, human apo-; Saline; SC; Rat; 2001; 7 days; Controls received mp w/ vehicle; dose-response (table 5); comparison of ingestion vs. mp; half-life (p. 295) estimated at 3.3 hours; cardiovascular; agent is a multifunctional iron and heparin binding protein.

P6564 Suzuki,O., Bishop,A.T., Sunagawa,T., Katsube,K., Friedrich,P.F. VEGF-promoted surgical angiogenesis in necrotic bone. MICROSURGERY 2004; 24(-1-):85-91. >>> Vascular endothelial growth factor 165; Phosphate buffer; albumin rabbit serum; Bone; Rabbit; 1003D; 3 days.

P7075 Thijssen,V.L.J.L., Brandwijk,R.J.M.G., Dings,R.P.M., Griffioen,A.W. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Experimental Cell Research 2004; 299(-2-):286-293. >>> Anginex; Saline; SC; Mice (nude); 2004; 20 days; Controls received mp w/ vehicle; cancer (melanoma, ovarian carcinoma).

P6633 Tsutsumi,N., Yonemitsu,Y., Shikada,Y., Onimaru,M., Tanii,M., Okano,S., Kaneko,K., Hasegawa,M., Hashizume,M., Maehara,Y., Sueishi,K. Essential role of PDGFR alpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo - Role of PDGFR alpha during angiogenesis. Circulation Research 2004; 94(-9-):1186-1194. >>> Antibody, polyclonal anti-PDGF-AA; IP; Mice; 1007D; 2001; 7 days; Cancer; cardiovascular.

P5722 Arras,M., Ito,W.D., Scholz,D., Winkler,B., Schaper,J., Schaper,W. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin.Invest 2003; 101(-1-):40-50. >>> Uridine, bromodeoxy-; IA (carotid); Rabbit; 2ML2; 3,7 days; Study proliferation of collateral arteries and capillaries.

P5643 Buttyan,R., Chichester,P., Stisser,B., Matsumoto,S., Ghafar,M.A., Levin,R.M. Acute intravesical infusion of a cobalt solution stimulates a hypoxia response, growth and angiogenesis in the rat bladder. Journal of Urology 2003; 169(-6-):2402-2406. >>> Uridine, bromodeoxy-; Saline; SC; Rat; 6 days.

P5515 Casanova,M.L., Blazquez,C., Martinez-Palacio,J., Villanueva,C., Fernandez-Acenero,M.J., Huffman,J.W., Jorcano,J.L., Guzman,M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J.Clin.Invest 2003; 111(-1-):43-50. >>> JWH-133; WIN-55,212-2; PBS; BSA; SC; Mice (nude); 2002; 11 days; Controls received mp w/ vehicle; cancer; cannabinoid agonists.

P7704 Cattaneo,M.G., Pola,S., Deho,V., Sanguini,A.M., Vicentini,L.M. Alprostadil suppresses angiogenesis in vitro and in vivo in the murine Matrigel plug assay. Br.J.Pharmacol. 2003/1; 138(-2-):377-385. >>> Prostaglandin E1; cyclodextrin; Saline, isotonic; SC; Mice; 4 days; Controls received mp w/ vehicle; animal info (C57/BL6, female, 6-8 weeks old).

P5940 Davies,G., Mason,M.D., Martin,T.A., Parr,C., Watkins,G., Lane,J., Matsumoto,K., Nakamura,T., Jiang,W.G. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostat e tumor growth and angiogenesis in vivo. International Journal of Cancer 2003; 106(-3-):348-354. >>> Hepatocyte growth factor; NK4; BSA; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; cancer (prostate); NK4 (HGF/SF antagonist) is recomb. human.

P6000 Dings,R.P.M., Yokoyama,Y., Ramakrishnan,S., Griffioen,A.W., Mayo,K.H. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Research 2003; 63(-2-):382-385. >>> Anginex; Bpep28; PBS; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; dose-response (fig.1, p. 383); cancer (ovarian); peptides; anginex is a potent angiogenesis inhibitor; Bpep28 is a control peptide without antiangiogenic activity.

P6636 Dings,R.P.M., van der Schaft,D.W.J., Hargittai,B., Haseman,J., Griffioen,A.W., Mayo,K.H. Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Letters 2003; 194(-1-):55-66. >>> Anginex; PBS; albumin, human serum; SC; Mice (nude); 2004; 28 days; Dose-response; cancer (ovarian); angiogenesis inhibitor; comparison of once or twice daily injections; alginate beads and minipumps; "Of the three administrative routes used (daily loco-regional bolus injections, continuous systemic delivery via osmotic mini-pumps and suspension in alginate beads implanted subcutaneously), continuous systemic administration of the peptide worked best." (p. 63).

P6050 Martin,T.A., Parr,C., Davies,G., Watkins,G., Lane,J., Matsumoto,K., Nakamura,T., Mansel,R.E., Jiang,W.G. Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis 2003; 24(-8-):1317-1323. >>> NK4; Hepatocyte factor/scatter factor; BSA; SC; Mice (nude); 2004; 4 weeks; Controls received mp w/ vehicle; cancer (breast); peptides; NK4 is a hepatocyte growth factor/scatter factor (HGF/SF) antagonist; angiogenesis research.

P5929 Namba,T., Koike,H., Murakami,K., Aoki,M., Makino,H., Hashiya,N., Ogihara,T., Kaneda,Y., Kohno,M., Morishita,R. Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation 2003; 108(-18-):2250-2257. >>> Immunoglobulin G; antibody, anti-vascular endothelial growth factor; IP; Rat; 28 days; Cardiovascular; peptides; pump model not stated; ischemia (hind-limb).

P9101 Reinmuth,N., Liu,W., Ahmad,S.A., Fan,F., Stoeltzing,O., Parikh,A.A., Bucana,C.D., Gallick,G.E., Nickols,M.A., Westlin,W.F., Ellis,L.M. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res. 2003/5/1; 63(-9-):2079-2087. >>> S247; SC; Mice; 28 days; Controls received mp w/ saline; cancer (colon); animal info (8 wks old, BALB/c); S247 is an Alphavbeta5 integrin antagonist; incorrectly states pump rate as 25 ul/hour; "no apparent toxicity from S247 or saline delivered via osmotic pump was observed" pg. 2081.

P6038 Sarlos,S., Rizkalla,B., Moravski,C.J., Cao,Z.M., Cooper,M.E., Wilkinson-Berka,J.L. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. American Journal of Pathology 2003; 163(-3-):879-887. >>> PD123319; IP; Rat (neonate); 2004; ; Controls received mp w/ vehicle; animal info (11 days old); insertion wound was then closed with a small stitch.

P5731 Sun,Y.J., Jin,K.L., Xie,L., Childs,J., Mao,X.O., Logvinova,A., Greenberg,D.A. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. Journal of Clinical Investigation 2003; 111(-12-):1843-1851. >>> Interleukin-1 receptor antagonist; Saline; sodium citrate; EDTA; Tween 80; SC; Rat; 2ML1; 3 days; Controls received mp w/ BSA "to control for nonspecific anti-angiogenic effects of stress associated with implantation of the osmotic minipump." (p. 2605); implantation of pumps delivering BSA caused no angiogenesis.

R0231 Freedman,S.B., Isner,J.M. Therapeutic angiogenesis for coronary artery disease. Ann.Intern.Med. 2002/1/1; 136(-1-):54-71. >>> Vascular endothelial growth factor; Periadventitial; Pig; 3,4 weeks; Replacement therapy (coronary ligation); cardiovascular; ischemia (cardiac); review, pg. 59.

P5664 Hagedorn,M., Zilberberg,L., Wilting,J., Canron,X., Carrabba,G., Giussani,C., Pluderi,M., Bello,L., Bikfalvi,A. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. Cancer Research 2002; 62(-23-):6884-6890. >>> Platelet factor 4 peptides; PBS; CSF/CNS (intratumoral); Mice (nude); 2004; 30 days; Controls received mp w/ vehicle; tissue perfusion (intratumoral); dose-response (p. 6888; fig 6); cancer; peptides; glioma; antiangiogenesis..

P5053 Harrigan,M.R., Ennis,S.R., Masada,T., Keep,R.F. Intraventricular infusion of vascular endothelial growth factor promotes cerebral angiogenesis with minimal brain edema. Neurosurgery 2002; 50(-3-):589-598. >>> Vascular Endothelial Growth Factor; PBS; Albumin, bovine serum; CSF/CNS; CSF/CNS (cortex); CSF/CNS (third ventricle); rat; 2001; 7 days; controls received mp w/ vehicle; dose response (p. 591); half-life = 6 min. (p. 594); peptides; brain tissue distribution; VEGF was human recombinant; benefits of continuous infusion p. 594.

P5039 Iversen,P.O., Iversen,P.O., Sorensen,D.R., Benestad,H.B. Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemias. LEUKEMIA 2002; 16(--):376-381. >>> Endostatin, LPS; PI-88; IP; mice; 2004; 4 weeks; cancer; recombinant human endostatin used; PI-88 is an anticoagulant mannopentaose phosphate sulfate; angiogenesis inhibitors. Agents given singly or concomitantly in same pump.

P5978 Luttun,A., Tjwa,M., Moons,L., Wu,Y., Angelillo-Scherrer,A., Liao,F., Nagy,J.A., Hooper,A., Priller,J., De Klerck,B., Compernolle,V., Daci,E., Bohlen,P., Dewerchin,M., Herbert,J.M., Fava,R., Matthys,P., Carmeliet,G., Collen,D., Dvorak,H.F., Hicklin,D.J., Carmeliet,P. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nature Medicine 2002; 8(-8-):831-840. >>> Placental growth factor; vascular endothelial growth factor; SC; Mice; 2001; 7 days; Angiogenesis.

P5055 Sasaki,K., Murohara,T., Ikeda,H., Sugaya,T., Shimada,T., Shintani,S., Imaizumi,T. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. Journal of Clinical Investigation 2002; 109(-5-):603-611. >>> Fibroblast growth factor 2; PBS; IA (femoral); Mice; 1007D; ; Controls received mp w/ vehicle; peptides.

P5200 Silvestre,J.S., Tamarat,R., Senbonmatsu,T., Icchiki,T., Ebrahimian,T., Iglarz,M., Besnard,S., Duriez,M., Inagami,T., Levy,B.I. Antiangiogenic effect of angiotensin II type 2 receptor in ischemia- induced angiogenesis in mice hindlimb. Circ.Res 2002/5/31; 90(-10-):1072-1079. >>> Angiotensin II; Mice (Knockout); 2004; 28 days; Controls received no pump; peptides; ischemia (hind-limb).

P5248 Wongtrakul,S., Bishop,A.T., Friedrich,P.F. Vascular endothelial growth factor promotion of neoangiogenesis in conventional nerve grafts. J Hand Surg.[Am.] 2002/3; 27(-2-):277-285. >>> Vascular endothelial growth factor; PBS; Albumin, rabbit serum; CSF/CNS (sciatic nerve); Rabbit; 1003D; 3 days; Controls received mp w/ vehicle; tissue perfusion (sciatic nerve graft); peptides; human recomb. VEGF used; transplantation;.

P7114 Carmeliet,P., Moons,L., Luttun,A., Vincenti,V., Compernolle,V., De Mol,M., Wu,Y., Bono,F., Devy,L., Beck,H., Scholz,D., Ackerk,T., DiPalma,T., Dewerchin,M., Noel,A., Stalmans,I., Barra,A., Blacher,S., VandenDriessche,T., Ponten,A., Eriksson,U., Plate,K.H., Foidart,J.M., Schaper,W., Charnock-Jones,S., Hicklin,D.J., Herbert,J.M., Collen,D., Persico,M.G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Medicine 2001; 7(-5-):575-583. >>> Placental growth factor-1, recomb. human; Mice; 2001; 7 days; Controls received mp w/ vehicle; replacement therapy (PgF -/- mice); cardiovascular; ischemia (retinal); embryology.

P4878 Iglarz,M, Silvestre,J.M., Duriez,M., Henrion,D., Levy,B. Chronic blockade of endothelin receptors improves ischemia-induced angiogenesis in rat hindlimbs through activation of vascular endothelial growth factor-NO pathway. Arterioscler Thromb Vasc Biol 2001; 21(--):1598-1603. >>> Endothelin-1; SC; IP; rat; 2002; 3 or 28 days; ET-1 infused at a subpressor dose of 2 pmol/kg/min; ischemia (hind-limb); cardiovascular.

R0222 Ng,Y.S, D'Amore,P.A  Current Controlled Trials in Cardiovascular Medicine 2001; 2(-6-):278-285. >>> Vascular endothelial growth factor; Pig; ; Cardiovascular; peptides; MRI; ALZET pumps mentioned on pg. 279.

P9107 Shusterman,S., Grupp,S.A., Barr,R., Carpentieri,D., Zhao,H., Maris,J.M. The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin.Cancer Res. 2001/4; 7(-4-):977-984. >>> TNP-470; Saline; IP; Mice (SCID); 1002; ; Controls received mp w/ vehicle; dose-response (pg 979 fig. 1b); comparison of SC injections vs. mp; half-life (p. 983) "2-6 min"; good methods pg. 978; cancer (neuroblastoma); post op. care (xylazine); animal info (4-6 wks old, athymic); 4.0 vinyl sutures used; TN-470 is an angiogenesis inhibitor; "our data demonstrate that continuous infusion of TNP-470 is feasible and that there is similar inhibition... as compared to conventional s.c. dosing." pg. 983.

P5758 Stern,J.W., Fang,J., Shusterman,S., Pierson,G., Barr,R., Pawel,B., Diller,L., Grupp,S.A. Angiogenesis inhibitor TNP-470 during bone marrow transplant: safety in a preclinical model. Clin Cancer Res 2001; 7(-4-):1026-1032. >>> TNP-470; Saline; IP; Mice (transgenic); 1002; 14 days; Controls received mp w/ vehicle; comparison of bolus injections vs. chronic mp; cancer; TNP-470 is an angiogenesis inhibitor; pump used to overcome the short half life of TNP-470 (p. 1030).

P6178 Swiercz,R, Keck,R.W, Skrzypcak-Jankun,E, Selman,S.H, Jankun,J  Oncology Reports 2001; 8(--):463-470. >>> Plasminogen activator inhibitor-1; Saline; SC; Mice (SCID); 2004; 28 days; Controls received mp w/ saline; dose-response (fig. 4 and 5); cancer (prostate); angiogenesis inhibitor.

P4991 Tanaka,T., Konno,H., Baba,S., Kanai,T., Matsumoto,K., Matsuda,I., Ohba,K., Ohta,M., Kamiya,K., Nakamura,S. Prevention of hepatic and peritoneal metastases by the angiogenesis inhibitor FR-118487 after removal of growing tumor in mice. Japanese Journal of Cancer Research 2001; 92(--):88-94. >>> NK4, recomb. human; BSA; saline; SC; Mice (nude); 2002; 1, 2, or 4 weeks; Controls received mp w/ vehicle; cancer (lung); animal info (6-8 wks old, male BALB, nu/nu); NK4 is a hepatocyte growth factor.

P3851 Powell,J.A., Mohamed,S.N., Kerr,J.S., Mousa,S.A. Antiangiogenesis efficacy of nitric oxide donors. Journal of Cellular Biochemistry 2000; 80(--):104-114. >>> Penicillamine, S-nitroso N-acetyl-; Glutathione, S-nitroso N-acetyl;; Saline; SC; mice; 2002; 14 days; controls received mp w/ vehicle; SNAP and SNAG are nitric oxide donors; angiogenesis inhibitors..